ReviewVaccines2018
Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults.
Review in Vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials.Infectious diseases of poverty · 2021Pooled it
- Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial.Nature communications · 2025Trial
- Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.Human vaccines & immunotherapeutics · 2020Trial
- Article
- Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season.Human vaccines & immunotherapeutics · 2024Article
- Influenza vaccine: a review on current scenario and future prospects.Journal, genetic engineering & biotechnology · 2023Review
- Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip Tetra) in South Korea.Infectious diseases and therapy · 2022Article
- Chinese expert consensus on immunoprophylaxis of common respiratory pathogens in children (2021 edition).Journal of thoracic disease · 2022Review
- An Overview of Influenza Viruses and Vaccines.Vaccines · 2021Review
- Article
- Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review.Frontiers in immunology · 2021Review
- Frailty Is Associated With Increased Hemagglutination-Inhibition Titers in a 4-Year Randomized Trial Comparing Standard- and High-Dose Influenza Vaccination.Open forum infectious diseases · 2020Article
- How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions.Influenza and other respiratory viruses · 2019Review
- High Public-Health Impact in an Influenza-B-Mismatch Season in Southern Italy, 2017-2018.BioMed research international · 2019Article
- The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity.Human vaccines & immunotherapeutics · 2019Review
- [The universal influenza vaccination in children with Vaxigrip TetraJournal of preventive medicine and hygiene · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the mid-1980s, two lineages of influenza B viruses have been distinguished. These can co-circulate, limiting the protection provided by inactivated trivalent influenza vaccines (TIVs). This has prompted efforts to formulate quadrivalent influenza vaccines (QIVs), to enhance protection against circulating influenza B viruses. This review describes the results obtained from seven phase III clinical trials evaluating the immunogenicity, safety, and lot-to-lot consistency of a new quadrivalent split-virion influenza vaccine (Vaxigrip Tetra
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.